Follow-On Biologics Study By FTC Aims “To Strike The Right Balance”

FTC appears skeptical of generic exclusivity for biologics, but the approval procedure would prove a critical factor.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet